SignalXSignalX

PCRX Pacira BioSciences, Inc.

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Pacira BioSciences, Inc. Overview

Pacira BioSciences, Inc. (PCRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Settlement with eVenus ANDA Filers allows limited generic sales starting early 2030, volume capped rising from high single-digit to high thirties % by late 2030s
  • • Updated risk: Patent infringement litigation expanded with new suits filed in Dec 2024, and new declaratory judgment action by eVenus ANDA Filers in 2025
+3 more insights

Get deeper insights on Pacira BioSciences, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.